HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2005.036368v1 65/2/222    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biggee, B A Articles by Silbert, J E Search for Related Content PubMed PubMed Citation Articles by Biggee, B A Articles by Silbert, J E

Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness

¹ Division of Rheumatology, Tufts New England Medical Centre, Boston, USA
² Connective Tissue Research Laboratory, Edith Nourse Rogers Memorial Veterans Hospital and Harvard Medical School, Brigham and Women’s Hospital, Division of Rheumatology/Immunology/Allergy, Bedford, USA

Correspondence to:
Correspondence to:
Dr J E Silbert
Edith Nourse Rogers Memorial Veterans Hospital, 200 Springs Road, Bedford, MA 01730, USA; jesilbert{at}aol.com

Background: Oral glucosamine preparations are widely used as a treatment for osteoarthritis, purportedly functioning by a variety of mechanisms suggested by results of in vitro experiments, and generally using glucosamine concentrations well in excess of 100 µmol/l.

Objective: To use high performance liquid chromatography with a high sensitivity Metrohm-Peak instrument for pulsed amperometric measurement of human serum glucosamine; a detection limit of 0.5 µmol/l at 1:10 serum dilution allowed measurement of low levels of glucosamine in human serum, which previously has not been possible.

Methods: Eighteen subjects with osteoarthritis were given 1500 mg of commercial glucosamine sulphate after an overnight fast, and serum was then obtained at baseline and every 15–30 minutes over 3 hours, and additionally, from two subjects at 5 and 8 hours. Urine samples were collected at baseline and 3 hours after ingestion from three subjects.

Results: Baseline glucosamine was below the detection limit of 0.5 µmol/l for all subjects, but after ingestion, glucosamine was detected in 17/18 subjects, beginning to rise at 30–45 minutes to a maximum at 90–180 minutes, with a range of 1.9–11.5 µmol/l (0.34–2 µg/ml).

Conclusion: This maximum concentration of 11.5 µmol/l has previously been shown to contribute less than 2% of the galactosamine incorporated into chondroitin sulphate in incubations of glucosamine with cultured human chondrocytes, and is a much lower concentration than the glucosamine concentrations claimed by other investigators to have various significant in vitro effects. This raises questions about current biological rationales for glucosamine use that were based on in vitro effects of glucosamine at much higher concentrations.

Abbreviations: BMI, body mass index; HPLC, high performance liquid chromatography; IL, interleukin

Keywords: osteoarthritis; glucosamine; human; serum; cartilage

This article has been cited by other articles:

				B. A Biggee, C. M Blinn, M. Nuite, T. E McAlindon, and J. E Silbert Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose Ann Rheum Dis, October 1, 2007; 66(10): 1403 - 1404. [Full Text] [PDF]

				W. A. Katz Themed Review: Nonpharmacologic Approaches to Osteoarthritis American Journal of Lifestyle Medicine, August 1, 2007; 1(4): 249 - 255. [Abstract] [PDF]

				N. Fulop, Z. Zhang, R. B. Marchase, and J. C. Chatham Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2227 - H2236. [Abstract] [Full Text] [PDF]

				B A Biggee, C M Blinn, M Nuite, J E Silbert, and T E McAlindon Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis Ann Rheum Dis, February 1, 2007; 66(2): 260 - 262. [Abstract] [Full Text] [PDF]

				J. C. Buckland-Wright, E. A. Messent, C. O. Bingham III, R. J. Ward, and C. Tonkin A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients Rheumatology, February 1, 2007; 46(2): 257 - 264. [Abstract] [Full Text] [PDF]

				R. Muniyappa, R. J. Karne, G. Hall, S. K. Crandon, J. A. Bronstein, M. R. Ver, G. L. Hortin, and M. J. Quon Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects Diabetes, November 1, 2006; 55(11): 3142 - 3150. [Abstract] [Full Text] [PDF]

				L. R. Tannock, E. A. Kirk, V. L. King, R. LeBoeuf, T. N. Wight, and A. Chait Glucosamine Supplementation Accelerates Early but Not Late Atherosclerosis in LDL Receptor-Deficient Mice J. Nutr., November 1, 2006; 136(11): 2856 - 2861. [Abstract] [Full Text] [PDF]

eLetters: